Coloplast A/S
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Coloplast A/S is a Danish multinational healthcare company specializing in the development, manufacture, and marketing of medical devices and services focused on personal and intimate healthcare needs. The company’s core products and services encompass Ostomy Care, Continence Care, Bowel Care, Voice & Respiratory Care, Advanced Wound Care, and Interventional Urology. Key product offerings include ostomy bags and accessories under brands such as SenSura; continence products including catheters, urisheaths, and anal irrigation systems branded as SpeediCath, Persiteen, and Conveen; wound care dressings such as foam and hydrocolloid dressings under Biatain and Comfeel; as well as skin care products including cleansers, moisturizers, skin protectants, and anti-fungals. Coloplast serves hospitals, healthcare institutions, wholesalers, retailers, and direct-to-consumer markets across 53 countries, with production facilities in Denmark, Hungary, France, China, and the US. Founded in 1957, the company is headquartered in Humlebæk, Denmark, with its North American presence based in Minneapolis, Minnesota. Recent major company changes include a strategic reorganization and expansion announced in 2025, whereby Coloplast incorporated Atos Medical and Kerecis into its portfolio and restructured its operations into two distinct business units: Chronic Care and Acute Care. This move aims to address different market dynamics and customer requirements while supporting the company’s 2030 strategy. The newly formed Chronic Care unit covers existing chronic product areas and Atos Medical’s voice and respiratory care business, with an independent Chronic Care R&D function established to accelerate innovation. The Acute Care unit includes the merged commercial organizations of AWD and Kerecis forming a Wound & Tissue Repair division focused on innovation leadership and global growth. Executive leadership updates accompanied this restructuring to align with the new strategic direction. Additionally, Coloplast hosted its Capital Markets Day in September 2025 to unveil a new five-year strategy called Impact4, which outlines long-term ambitions and growth initiatives. The company has also addressed recent operational challenges such as product recalls in its Interventional Urology segment while maintaining 6% organic growth in Q2 2025 despite soft performance in parts of Ostomy Care. Coloplast operates primarily in the healthcare industry segments of ostomy, continence, wound and skin care, interventional urology, and voice and respiratory care. Its target customers include healthcare professionals, hospital purchasers, group purchasing organizations, nurses, and patients requiring intimate healthcare solutions. The company maintains a strong global presence with sales activities and direct supply chains spanning Europe, North America, and Asia. Its substantial R&D investment and diversified product portfolio underscore its market leadership in ostomy and continence care worldwide. Coloplast’s comprehensive healthcare solutions and recent strategic realignment position it for sustained innovation and growth in the intimate healthcare space.
Coloplast: Went 'BUY' A Bit Early
Coloplast A/S (CLPBY) Q2 2026 Earnings Call Transcript
Coloplast: The Market Is Throwing Away A High-Quality Compounder
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
Coloplast appoints Gavin Wood as new CEO
Coloplast A/S - Updated Financial Calendar 2025-26
Coloplast A/S (CLPBY) Q1 2026 Earnings Call Transcript
Coloplast A/S - Interim Financial Report, Q1 2025/26
Coloplast A/S - Interim Financial Report, Q1 2025/26
Coloplast announces changes to Executive Leadership Team
Coloplast A/S (CLPBY) Shareholder/Analyst Call Transcript
Coloplast A/S - Decisions at the Annual General Meeting 2025
Coloplast A/S (CLPBY) Q4 2025 Earnings Call Transcript
After A 50% Decline, Coloplast Might Finally Be Worth Buying
Coloplast interim CEO Lars Rasmussen will step down from the Board at the upcoming Annual General Meeting
Coloplast A/S - Financial Calendar 2025-26
Coloplast A/S (CLPBY) Capital Markets Day 2025 Transcript
Coloplast A/S (CLPBF) Q3 2025 Earnings Call Transcript
Coloplast A/S – Updated presenters list for Capital Markets Day on 2 September 2025